Zimmer Biomet Holdings Inc. (ZBH) shares plunged over 5% in the pre-market trading session on Thursday, despite reporting better-than-expected Q4 2024 earnings. The medical device maker's disappointing full-year 2025 profit forecast overshadowed its quarterly results.

For Q4 2024, Zimmer Biomet reported adjusted earnings of $2.31 per share, narrowly beating analysts' expectations of $2.30. Revenue of $2.02 billion also edged past estimates of $2.01 billion, driven by strong demand for its hip and knee implants as well as sports medicine and trauma care products.

However, the company's full-year 2025 adjusted profit guidance of $8.15 to $8.35 per share fell short of Wall Street's consensus estimate of $8.56. Zimmer Biomet expects a 1.5% to 2% negative impact on revenue due to a stronger U.S. dollar. Additionally, its recent acquisition of orthopedic surgical device maker Paragon 28 is expected to weigh on earnings by around 10 cents per share.